伊顿制药公司获得Auson制药公司罕见病候选产品SYS-001的美国权利，用于治疗扩张性浅层婴儿血管瘤

2026-08-05 18:53

ASN-001 targets the substantially larger population of moderate infantile hemangiomas currently treated off-label with topical timolol
Complementary product to HEMANGEOL® (propranolol hydrochloride) oral solution, positioning Eton, if approved, to treat full spectrum of infantile hemangioma patients
ASN-001 Phase II/III trial results showed week 24 elimination or near-elimination rates of 56% (BID) and 42% (TID) compared with 15% for placebo
Anticipate NDA submission in 2H 2027 for potential approval and launch in 2028
Estimated 20,000 to 30,000 patients annually could be candidates for ASN-001, pathway to potentially be the largest revenue generating product in Eton’s portfolio
Leverages Eton’s existing pediatric dermatology commercial infrastructure and expands Company’s leadership in infantile hemangioma space